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Abstract
The aim of this study was to examine the role of cyclooxygenase-2 (COX-2) and downstream signaling of prostanoids in the
pathogenesis of pulmonary hypertension (PH) using mice with genetically manipulated COX-2 expression. COX-2
knockdown (KD) mice, characterized by 80–90% suppression of COX-2, and wild-type (WT) control mice were treated weekly
with monocrotaline (MCT) over 10 weeks. Mice were examined for cardiac hypertrophy/function and right ventricular
pressure. Lung histopathological analysis was performed and various assays were carried out to examine oxidative stress, as
well as gene, protein, cytokine and prostanoid expression. We found that MCT increased right ventricular systolic and
pulmonary arterial pressures in comparison to saline-treated mice, with no evidence of cardiac remodeling. Gene expression
of endothelin receptor A and thromboxane synthesis, regulators of vasoconstriction, were increased in MCT-treated lungs.
Bronchoalveolar lavage fluid and lung sections demonstrated mild inflammation and perivascular edema but activation of
inflammatory cells was not predominant under the experimental conditions. Heme oxygenase-1 (HO-1) expression and
indicators of oxidative stress in lungs were significantly increased, especially in COX-2 KD MCT-treated mice. Gene
expression of NOX-4, but not NOX-2, two NADPH oxidase subunits crucial for superoxide generation, was induced by ,4-
fold in both groups of mice by MCT. Vasodilatory and anti-aggregatory prostacyclin was reduced by ,85% only in MCT-
treated COX-2 KD mice. This study suggests that increased oxidative stress-derived endothelial dysfunction,
vasoconstriction and mild inflammation, exacerbated by the lack of COX-2, contribute to the pathogenesis of early stages
of PH when mild hemodynamic changes are evident and not yet accompanied by vascular and cardiac remodeling.
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Introduction
Prostacyclin (PGI2) is a potent vasodilator and platelet inhibitor
produced in blood vessels by the enzymatic activity of cyclooxy-
genases (COX-1 and COX-2) and prostacyclin synthase (PGIS) [1].
PGI2 has been shown in vitro [1] and in vivo [2,3] to modulate the
vasoconstrictor and platelet aggregatory activities of thromboxane
A2 (TXA2), a COX-derived prostanoid produced mainly by
activated platelets via COX-1 during hemostasis. A disrupted
interplay between PGI2 and TXA2 levels has been implicated in the
pathogenesis of pulmonary hypertension (PH), a severe condition
characterized by irreversible remodeling of pulmonary resistive
vessels, increased pulmonary vascular tone and in situ thrombosis
[4,5,6]. PGIS is down-regulated in patients with PH [7] and other
chronic lung diseases [8] and transgenic animal models, over-
expressing PGIS or with deletion of the PGI2 receptor (IP), have
unequivocally demonstrated a protective role of PGI2 in settings of
PH [9,10,11]. To date, PGI2 analogs are among the few therapeutic
options available to improvehemodynamic parametersand survival
of patients with PH. A direct vasodilatory effect on pulmonary
vasculature, modulation of arterial thrombosis and inhibition of
vascular remodeling, canall account for these beneficial effects [12].
On the other hand, COX-1 inhibitors or TXA2 receptor
antagonists improve PH only partially since other mechanisms of
platelet aggregation, via ADP, collagen, serotonin and thrombin,
may sustain intra-pulmonary arterial thrombosis and progression of
the disease, even in settings of profound TXA2 inhibition [13].
COX-2 inhibitors (coxibs) represent a subgroup of non-steroidal
anti-inflammatory drugs (NSAID) that target selectively COX-2
and spare almost completely COX-1 activity. Administration of
celecoxib, one of the first COX-2 inhibitors developed, to healthy
humans profoundly suppressed in vivo PGI2 biosynthesis leaving
TXA2 production intact [14]. Moreover, coxibs consistently
increased the risk of cardiovascular events, related mostly to
thromboembolic events, compared to non-selective NSAIDs or
placebo [15]. In hypoxia-induced PH models, administration of
COX-2 inhibitors [16] or genetic knock out of COX-2 [17,18,19]
decreased PGI2 levels, failed to reduce hypoxia-induced throm-
boxane production and exacerbated the rise in pulmonary
pressures and vascular remodeling.
In the present study, we employed a novel mouse model of
COX-2 inhibition, that mimics coxib administration, character-
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23439ized by a knock down of COX-2 (COX-2 KD) expression (<80%)
with disrupted PGI2 production, but with intact COX-1-derived
TXA2 biosynthesis, and increased tendency to thrombogenesis
[20], in monocrotaline (MCT)-induced PH.
The MCT-induced PH model is well established in rats but it
remains controversial in mice since the severity of MCT-induced
PH and associated pulmonary and cardiac histopathological
changes are variable [21,22,23,24,25]. This is attributed mainly
to species- and strain-specific differences in hepatic cytochrome
P450 enzymes required for MCT biotransformation into the active
MCT pyrrole, rendering this model less reproducible in mice than
in rats [26,27]. However, more recently, repeated MCT
administration at high doses (600 mg/kg body weight) and/or
for prolonged treatment (8 weeks) than in previously employed
studies, appears to more consistently and reproducibly induce PH
in mice [28,29,30,31]. Despite hypoxia being most commonly
used in mice as a model of PH, we opted for the use of MCT
because, in contrast to hypoxia-induced PH. MCT-induced PH is
characterized by increased pulmonary vascular permeability and
remodeling consequent to direct injury of MCT to the alveolar
capillary endothelium [32,33]. In addition, this model has not
previously been studied with COX-2 modulation. Lastly, MCT
has been reported to increase pulmonary resistance in dogs, at
least in part, by increasing arterial thrombosis, associated with
increased circulating thromboxane levels, that is ameliorated after
PGI2 infusion [34].
In this study, we aimed to elucidate the role of COX-2, an
abundant source of PGI2, in the pathogenesis of PH by comparing
COX-2 KD mice and WT controls after pulmonary endothelial
injury induced by MCT administration. Here, we describe our
findings and the limitations of using MCT as a model of PH in
mice.
Results
Monocrotaline induced mild pulmonary hypertension
(PH) in WT and COX-2 KD mice
Preliminary experiments aimed to assess the feasibility of
consistently inducing PH in mice by monocrotaline (MCT)
administration and the dosing regimen required. MCT in the
range 50–300 mg/kg BW, weekly for 4 weeks, failed to
significantly increase right ventricular pressure, used as an index
of pulmonary artery pressure, in mice. At 300 mg/kg BW MCT
dose, right ventricular pressures showed a modest increase versus
saline treatment but did not reach statistical significance (WT/
saline: 6.660.8, n=4; COX-2KD/saline: 6.760.7, n=6; WT/
MCT: 9.860.9, n=5; COX-2KD/MCT: 8.262.7 mmHg,
n=3). Moreover, immunolabeling of lung sections with a-smooth
muscle actin did not reveal any significant increases in pulmonary
arteriole muscularization in MCT-treated mice, compared to the
saline-treated group (data not shown). Therefore, in the current
study, we increased the MCT dose to 600 mg/kg once weekly for
10 weeks. A similar regimen has been recently used by several
investigators to consistently induce PH in mice [28,29,30,31,35].
MCT treatment induced a consistent body weight loss
compared to saline-treated mice (change BW: WT/saline:
+7.761.2%, n=6; COX-2 KD/saline: +6.362.1%, n=6; WT/
MCT: 210.563.2%, n=11; COX-2 KD/MCT: -9.762.8%,
n=5; p,0.05 saline vs MCT; n indicates number of animals that
completed the study) over the 10-week study period. Unexpect-
edly, 14 of 19 COX-2 KD mice died or experienced duress
requiring euthanasia compared to only 3 of 14 MCT-treated WT
mice (overall survival rate: 79% for MCT-treated WT, n=14;
26% for MCT-treated COX-2 KD, n=19; 100% saline-treated
WT, n=6 and 100% saline-treated COX-2 KD, n=6;
p=0.0006, WT-MCT vs COX-2 KD-MCT, Mentel-Cox test)
(Fig. S1). Post-mortem histopathological analysis on 2 WT and 3
COX-2 KD MCT-treated mice that required euthanasia revealed
acute hepatic necrosis that was more pronounced in COX-2 KD
mice. MCT at 600 mg/kg BW induced a modest but significant
increase in right ventricular end systolic pressure in comparison to
saline-treated mice (WT/saline: 13.260.5, n=6; COX-2KD/
saline: 12.160.6, n=5; WT/MCT: 16.160.3, n=5; COX-2
KD/MCT: 16.760.3 mmHg, n=3; mean6SEM, p,0.05 MCT
vs saline; Figure 1A and B), with no increase in right ventricular
end diastolic pressure (WT/saline: 3.660.8, n=6; COX-2KD/
saline: 4.560.6, n=5; WT/MCT: 5.460.4, n=5; COX-2KD/
MCT: 6.261.9 mmHg, n=3; mean6SEM, NS; Figure 1A and
B). Doppler analysis at the level of the pulmonary valve, recorded
by ultrasonography on lightly anesthetized mice (heart rate 400–
500 bpm), demonstrated an increase in the pulmonary arterial
blood flow gradient and velocity in systole after MCT treatment
(Table 1). Left ventricular function and dimensions were similar
in all treatment groups (Table S1). These results are consistent
with an increased right ventricular afterload during systole
indicating that MCT increased pulmonary artery pressure mainly
by increasing pulmonary vascular resistance, with no impairment
of left ventricular function.
Vasoconstrictors in lungs after MCT
We investigated the expression of endothelin-1 receptor A
(ETR-A) as one of the possible molecular mechanisms contribut-
ing to increased pulmonary vascular resistance in response to
MCT. Endothelin-1 is the most potent and long-lasting endoge-
nous vasoconstrictor produced by endothelial cells and is a
mitogen for vascular smooth muscle cells [36,37,38]. Endothelin-1
circulating levels are increased in patients with PH [39] and ETR
antagonists are commonly used to treat PH [40,41]. We found that
ETR-A gene expression was significantly induced in response to
MCT, as measured by quantitative PCR on lung tissue
homogenates (fold-increase vs saline: 2.360.4 in WT/MCT,
n=8; 2.260.6, n=7 in COX-2 KD/MCT; p,0.05). Therefore,
in MCT-induced PH in mice, the endothelin-1 signaling pathway
appears to be upregulated and may contribute to increased
pulmonary vascular resistance in accordance with observations in
humans. We next measured thromboxane B2 (TXB2), a stable
metabolite of TXA2, a potent vasoconstrictor, smooth muscle cell
mitogen and platelet aggregator, that might also contribute to
increase pulmonary vascular resistance after MCT administration.
Moreover, thromboxane levels have been shown to increase in
humans [4], rats [16] and mice [17] affected by pulmonary
hypertension. TXB2 levels measured in BAL fluid collected at
study endpoint, showed a tendency to increase in a similar fashion
in WT and COX-2 KD mice after MCT (WT/saline: 92624,
range 35–166, n=6; COX-2 KD/saline: 80617, pg/ml, range
30–150, n=6; WT/MCT: 3876218, range 117–2107, n=9;
COX-2 KD/MCT: 4556224 pg/ml, range 120–1437, n=6,
NS). Although the wide ranges of TXB2 levels in BAL fluids
suggest that the degree of platelet activation within the lungs in
response to MCT is variable, nonetheless thromboxane may
contribute to pulmonary vessel occlusion and increase pulmonary
vascular tone in MCT-treated mice.
Prostacyclin and PGE2 in MCT-treated lungs
6-keto-PGF1a, the stable hydrolysis metabolite of PGI2, was
measured in BAL fluid as an index of PGI2 production in the
lungs. Levels of this prostanoid after 10 wk MCT treatment were
more than 2.5-fold lower in COX-2 KD than WT mice
COX-2 Knockdown Mice in PH
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ingly, levels in control COX-2 KD mice were significantly higher
than control WT (882563617, n=6 vs 41246864 pg/ml, n=6;
p,0.05). These findings suggest that COX-2 KD mice produce
high basal levels of PGI2 in the lungs, presumably from COX-1,
an abundant source of PGI2 [42], despite systemic PGI2
biosynthesis in these mice being reduced <50% compared to
WT mice [20], as measured by the main urinary metabolite 2,3-
dinor-6-ketoPGF1a. However the capacity of the lungs to produce
PGI2 is drastically reduced after 10 wk MCT treatment (<85%
reduction in 6-keto-PGF1a, p=0.032 vs COX-2 KD/saline),
when COX-2 expression is knocked down.
In contrast, levels of PGE2 did not change significantly in BAL
at study end-point after MCT treatment or between WT and
Figure 1. Monocrotaline-induced pulmonary arterial hypertension in mice. A. Representative right ventricular pressure (RVP) tracings
recorded after 10 wk of monocrotaline (MCT) or saline administration, by inserting a pressure transducer directly into the right ventricle. B. Right
ventricular pressures (RVP) were calculated from tracings as in panel A, by averaging 15 s intervals of continuous recording. WT/saline, n=6; WT/MCT,
n=5; COX-2 KD/saline, n=5; COX-2 KD/MCT, n=3. mmHg, millimeters of mercury. *, p,0.05 vs saline.
doi:10.1371/journal.pone.0023439.g001
COX-2 Knockdown Mice in PH
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MCT: 15206278, n=8; COX-2 KD/sal: 24306259, n=4;
COX-2 KD/MCT: 18326424 pg/ml, n=5). Similarly, systemic
PGE2 production, measured as the urinary stable metabolite
PGEM (9,15-dioxo-11a-hydroxy-2,3,4,5-tetranor-prostane-1,20-
dioic acid), did not differ significantly between treatment groups
(data not shown).
Right ventricular hypertrophy after MCT
Since chronic PH can lead to right ventricular hypertrophy and
failure in response to increased vascular resistance in the
pulmonary circulation, we measured right ventricular wall
thickness in vivo by echocardiography and by histopathological
analysis of heart sections at study end point. Right ventricular
hypertrophy was not evident after ten weeks MCT treatment in
comparison to saline-treated mice (WT/saline: 0.3360.02 mm,
n=6; COX-2 KD/saline: 0.3260.02 mm, n=5; WT/MCT:
0.3760.02, n=10; COX-2 KD/MCT: 0.4060.03, n=7; NS).
These results were confirmed post-mortem on H&E stained heart
sections in which there were no significant cardiac morphological
differences between treatment groups (data not shown).
Pulmonary vascular remodeling
Muscularizationofresistivevessels,plexiformlesionsandvasculitis
leading to complete vessel obliteration have been described as
hallmarks of pulmonary hypertension in humans and in animals,
albeit in the latter with different degrees of severity depending on the
model [32]. These morphological changes together with vasocon-
striction, thrombotic events and inflammation, are known to
contribute to the pathophysiology of PH. In our experimental
conditions, both WT and COX-2 KD MCT-treated mice
experienced a mild remodeling of pulmonary arterioles compared
to saline-treated mice, with perivascular edema (Figure 2).
Inflammation is minimal in MCT-treated WT and COX-2
KD mice
Since studies on animal models of PH and humans suggest that
inflammation may play an important role in the pathogenesis of
PH, we investigated the expression of several inflammatory genes
and cytokines in whole lung homogenates, BAL fluid and plasma
collected at study endpoint. We found that COX-2 was not
significantly induced in MCT-treated mice compared to saline
controls, as revealed by lung section immunolabeling (data not
shown). Western blot analysis on whole lung homogenates showed
that COX-2 protein expression was comparable between saline-
and MCT-treated WT mice and drastically reduced in COX-2
KD mice (Figure 3). Similar results were obtained for COX-2
mRNA levels measured by quantitative PCR with no significant
differences between saline- and MCT-treated groups (WT/saline:
0.7960.1, n=6; COX-2 KD/saline: 0.0160.005, n=6; WT/
MCT: 1.0260.14, n=10; COX-2 KD/MCT: 0.0360.02, n=7;
p,0.001 COX-2 KD vs WT). As expected, levels of COX-2
mRNA were reduced by . 90% in COX-2 KD lungs compared
to WT. COX-1 protein expression was similar in WT and COX-2
KD lungs and remained constant after MCT (Figure 3). COX-1
and COX-2 levels in COX-2 KD mice are in accordance with the
levels of expression previously found in other cell types and tissues
[20]. Tumor necrosis factor-a (TNFa), a potent cytokine produced
mainly by activated macrophages, was unchanged after MCT
treatment in both WT and COX-2 KD mice (assessed in lung
mRNA extracts and in BAL fluid, data not shown). Similar to
TNFa, several other inflammatory cytokines (IL-6, IL-10, MCP-1,
IFN-c, IL-12p70) assessed by bead array on BAL and plasma
samples, were below the detection limit of the assay (5–53 pg/ml)
in all animals studied (WT/Saline n=3, WT/MCT, n=6; COX-
2 KD/Saline n=3, COX-2 KD/MCT, n=3; data not shown).
We next analyzed NF-kB protein expression since NF-kB
activation is known to induce the transcription of inflammatory
cytokines and proteins, including COX-2. As depicted in
Figure 4, NF-kB subunit p52 was not significantly different in
MCT-treated mice with no difference between WT and COX-2
KD mice. A qualitative differential cell analysis on bronchoalve-
olar lavages at study end-point revealed relative increases in
percentage of neutrophils (WT/saline: 1.660.8%, n=5 vs WT/
MCT: 26.867.9%, n=9; p,0.05; COX-2 KD/saline: 160.6%,
n=6 vs COX-2 KD/MCT: 18.764.6%, n=6; p,0.05) and
lymphocytes (WT/saline: 5.261.8%, n=5 vs WT/MCT:
11.663.4%, n=9; NS; COX-2 KD/saline: 561.7%, n=6 vs
COX-2 KD/MCT: 10.261.8%, n=6; p,0.05) after MCT
treatment. The relative number of monocytes was not significantly
different between saline- and MCT-treated animals (data not
shown). This is consistent with mild, ongoing pulmonary
inflammation. This was also noted histologically, and character-
ized by mild perivascular edema and small increases, predomi-
nantly in neutrophils, within the alveolar interstitium and
surrounding pulmonary arterioles (Figure 2). No differences were
detected between WT and COX-2 KD animals treated with MCT
and no histological evidence of thrombosis was noted.
Expression of endothelial markers and oxidative stress
(eNOS, PGIS, HO-1 and nitrotyrosine) in MCT-treated
lungs
MCT has been shown to induce megalocytosis, enlargement of
the Golgi apparatus and block in mitosis of pulmonary endothelial
Table 1. Pulmonary artery blood velocity is increased after MCT treatment.
VTI,cm
Mean Gradient,
mmHg
Peak Gradient,
mmHg
Mean Velocity,
mm/s
Peak
Velocity, mm/s
WT/saline (n=6) 2.5260.2 0.2860.04 1.460.19 260.8618.8 583.8638
WT/MCT (n=11) 3.0660.18* 0.560.09* 2.5260.51* 343628* 764665*
COX-2KD/saline (n=6) 2.5360.29 0.2860.03 1.4260.17 261616 590635
COX-2KD/MCT (n=6) 3.8460.4*
# 0.8160.15* 4.4560.94* 438643* 10276108*
#
Velocity-time integral (VTI, cm), mean and peak gradient (mmHg) and mean and peak velocity (mm/s) of blood flow in the pulmonary artery were measured from
Doppler waveforms acquired by ultrasound imaging. Number of mice for each group is in parentheses. Mean6SE;
*p,0.05 vs saline;
#p,0.05 vs WT/MCT.
doi:10.1371/journal.pone.0023439.t001
COX-2 Knockdown Mice in PH
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by which MCT induces pulmonary damaging effects are not fully
elucidated, endothelial injury within pulmonary vasculature is
believed to be one of the most prominent. We therefore
investigated the expression of several genes related to endothelial
function. We found that lung expression of endothelial nitric oxide
synthase (eNOS) and prostacyclin synthase (PGIS), the major
source of two vasodilators NO and PGI2, produced by endothelial
cells, was not significantly affected by MCT in both WT and
COX-2 KD mice after 10-weeks of treatment (Figure 5).
Heme oxygenase-1 (HO-1) is a heat shock protein induced in
endothelial cells by a variety of stresses, including oxidative stress.
Figure 2. Minimal vascular pulmonary remodeling after MCT. A. Representative images 400x indicating only mild thickening of pulmonary
arterioles from WT and COX-2 KD mice after MCT compared to saline. Lower panels are representative of WT and COX-2 KD MCT-treated mice that
required euthanasia. Sections were stained with H&E. Lungs from 38 mice were evaluated microscopically with 2 lung sections/mouse, as follows: WT/
saline, n=6; COX-2 KD saline, n=6; WT/MCT, n=14; COX-2 KD/MCT, n=12. B. Representative photomicrographs at 200x (a, c) of lung sections from a
COX-2 KD MCT-treated mouse showing pulmonary mild perivascular edema with neutrophil infiltration in small arterioles. Boxed areas from a and c
are shown at 400x in b and d.
doi:10.1371/journal.pone.0023439.g002
Figure 3. COX-1 and COX-2 expression in MCT-treated lungs. Western blot analysis for COX-2, COX-1 and b-actin expression in whole lung
homogenates from WT and COX-2 KD mice treated with saline or MCT for 10 weeks. Each lane represents lung proteins from one mouse. WT/saline,
n=3; WT/MCT, n=5-6; COX-2 KD/saline, n=3; COX-2 KD/MCT, n=3–4.
doi:10.1371/journal.pone.0023439.g003
COX-2 Knockdown Mice in PH
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MCT-induced PH in mice [35]. In our experimental conditions,
HO-1 mRNA from lung extracts, was induced by 3.4-fold in
MCT-treated WT and by 5.7-fold in COX-2 KD mice compared
to saline controls (Figure 6). HO-1 up-regulation at study
endpoint suggests that MCT-treated lungs experienced a sustained
oxidative stress during the treatment period. We therefore
measured indirectly oxidative stress by DHE fluorescence of lung
sections. MCT treatment dramatically increased this parameter in
WT and COX-2 KD lung sections compared to saline treatment.
DHE staining was particularly intense around pulmonary
arterioles (Figure 7A and quantitation in 7B). As another
measure of oxidative stress in MCT-treated lungs, we assessed
nitrotyrosine content in proteins from whole lung homogenates by
Western blotting. As depicted in Figure 8A (quantitation in
graph, 8B), MCT treatment induced nitration of tyrosine residues
in both WT and COX-2 KD mice.
NADPH oxidase is considered a major source of superoxide
anion in vascular tissues [45]. We found that NOX-4, a NADPH
oxidase abundantly expressed in vascular smooth muscle cells [46]
and endothelial cells [47], was upregulated by < 4-fold in response
to MCT (3.960.6 in WT/MCT, n=9 and 4.160.9 in COX-2
KD/MCT, n=7 compared to saline; Figure 9). Whole lung
expression of NOX-2/gp91phox subunit, considered the predom-
inant catalytic subunit of NADPH oxidase in phagocytic cells, and
extracellular superoxide dismutase (EC-SOD), a known O2
.2
scavenger, did not change significantly after MCT (data not
shown). Taken together, these results suggest that sustained
oxidative stress and endothelial dysfunction may contribute to
the pathogenesis of MCT-induced PH and that in COX-2 KD
lungs oxidative stress is exacerbated compared to WT.
Discussion
In experimental animal models with COX-2 null mice and
COX-2 inhibitors a protective role of COX-2 in the development
of PH is indicated but the exact signaling pathways are poorly
understood. Here we studied the effects of COX-2 modulation in
MCT-induced PH using unique induced mutant mice, genetically
manipulated to express <20% COX-2 (COX-2 KD). The
advantage of COX-2 KD mice is that they mimic the
administration of COX-2 selective inhibitors, i.e. incomplete
suppression of COX-2 products, without severe phenotypic
abnormalities, such as renal defects, associated with COX-2 null
mice [48,49]. In the attempt to identify the molecular mechanisms
contributing to MCT-induced PH, we analyzed lung and heart
samples from WT and COX-2 KD at study end point (10 wk),
when hemodynamic changes in right ventricular systolic pressure
(RVSP) and pulmonary arterial pressures, were evident but rather
modest.
PH is a complex disease and, to date, the lack of reliable animal
models that recapitulate all the features of human PH has limited
the discovery of new therapeutics to treat this severely disabling
disease. One of the main features of human PH is loss and pruning
of pulmonary peripheral vessels and muscularization of small and
medium pulmonary arterioles. These morphological changes are
considered the hallmarks of PH in humans and current animal
models and they are known to contribute to increased lung
vascular resistance leading to an elevation in pulmonary arterial
pressure. In our experimental conditions, MCT administration did
not result in a pronounced remodeling of pulmonary resistive
vessels and right ventricles, as usually occurs in advanced PH.
Despite the absence of detectable morphological changes in lungs
and heart and only modest increases in RVSP, we found that
oxidative stress, as evidenced by remarkable HO-1 induction,
superoxide production and increased expression of nitrated
tyrosine residues in lungs was the paramount pulmonary effect
of MCT in mice. Extracellular superoxide dismutase, a known
antioxidant protein, did not change significantly in MCT-treated
mice suggesting that there is an increase in superoxide production
(measured by DHE fluorescence) rather than a decrease in
Figure 4. NF-kB expression in lungs is unchanged after MCT. Representative immunoblot for NF-kB p52 subunit with b-actin normalization in
WT and COX-2 KD whole lung homogenates. WT/saline, n=6; WT/MCT, n=11; COX-2 KD/saline, n=6; COX-2 KD/MCT, n=7.
doi:10.1371/journal.pone.0023439.g004
Figure 5. eNOS and PGIS expression in lungs after MCT treatment. eNOS and PGIS protein levels, measured in whole lung homogenates,
were not significantly affected by MCT in WT and COX-2 KD mice in comparison to saline-treated mice. b-actin is shown for normalization. WT/saline,
n=6; WT/MCT, n=11; COX-2 KD/saline, n=6; COX-2 KD/MCT, n=7.
doi:10.1371/journal.pone.0023439.g005
COX-2 Knockdown Mice in PH
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23439scavenging capacity of the lungs in these settings. Moreover, in
response to MCT we found a <2-fold induction of ETR-A, the
major receptor responsible for the vasoconstrictive activity of
endothelin-1, and an increase of vasoconstrictor and prothrombo-
tic molecule TXA2 in BAL fluid, compared to saline-treated mice
and with no significant difference between WT and COX-2 KD
mice. Taken together, these results suggest that oxidative stress
and increased pulmonary vasoconstriction, may both contribute to
pulmonary vascular functional impairment leading to the modest
hemodynamic changes observed in MCT-treated mice. These
results are in accordance with several studies showing that
endothelial dysfunction in pulmonary vasculature, disrupted
balance of vasoactive substances (endothelin-1 and NO, among
others) and impaired endothelium-dependent pulmonary artery
relaxation are observed prior to vascular remodeling or plexiform
lesions in humans with PH [50] and animal models [51,52].
Several enzymes including NADPH oxidase, uncoupled eNOS,
xanthine oxidase, those involved in mitochondrial respiratory
electron transport, lipoxygenases, COX, myeloperoxidases and
cytochrome P450 can contribute to the production of reactive
oxygen species (ROS) in physiological conditions. NADPH
oxidase and uncoupled eNOS activity are recognized as the most
abundant source of ROS in vascular tissues in cardiovascular
diseases characterized by endothelial dysfunction [53]. NOX-4, a
constitutively active gp91phox/NOX-2 subunit homolog and
primary source of NADPH oxidase catalytic activity and ROS
generation in VSMC [46] and endothelial cells [47], was induced
by 4-fold in the lungs of MCT-treated mice and may be
responsible for the increased production of superoxide in these
settings. We did not find significant changes in endothelial NOS
(eNOS), in whole lung homogenates after MCT and no difference
between WT and COX-2 KD mice. Despite unchanged overall
eNOS protein levels, we cannot exclude that uncoupled eNOS
activity may in part contribute, in addition to NOX-4, to increased
superoxide production in response to MCT. Indeed, recent studies
linked oxidative stress-derived endothelial dysfunction due to
NADPH oxidase- and/or uncoupled eNOS-derived superoxide, to
Figure 7. Oxidative stress is exacerbated in lungs from COX-2 KD mice after MCT treatment. A. Images from MCT-treated mice (20x
objective) revealing intense DHE fluorescence in pulmonary arterioles. The image of a DHE-fluorescing arteriole (40x) from a saline control was
included for comparison to indicate background fluorescence. B. Intensities of DHE fluorescence are summarized in graph format and expressed as
integrated optical densities (IOD). Lung sections (n=7–27) from 4–7 mice from each treatment group are represented as averaged fluorescence
values. DHE, dihydroethidine. *, p,0.05 vs saline; #,p ,0.05 vs MCT-treated WT.
doi:10.1371/journal.pone.0023439.g007
Figure 6. HO-1 mRNA is induced in response to MCT. HO-1
mRNA expression detected by quantitative RT-PCR in whole lung
extracts. GADPH was used as endogenous control. Results were
calculated as fold-change relative to reference cDNA, as described in
Methods and expressed as fold-change relative to WT/saline. WT/saline,
n=6; WT/MCT, n=10; COX-2 KD/saline, n=6; COX-2 KD/MCT, n=6.
*p ,0.05 vs saline; #,p ,0.05 vs MCT-treated WT.
doi:10.1371/journal.pone.0023439.g006
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[56,57,58,59,60].
NOX-2/gp91phox subunit, the NADPH oxidase catalytic
moiety in phagocytic cells, such as neutrophils, was not affected
by MCT treatment. The number of monocytes and levels of
TNFa and several other inflammatory cytokines produced mostly
by activated macrophages (IL-6, IL-10, MCP-1, IFN-c, IL-12p70)
were unchanged before and after MCT despite mild increases in
the proportion of neutrophils and lymphocytes and perivascular
edema. Similarly, PGE2 in BAL fluid did not change significantly
after MCT treatment. Furthermore NF-kB, a transcription factor
activated by inflammatory stimuli, remained unchanged after
MCT in both WT and COX-2 KD mice. However, since our
Western blot analysis was limited to whole lung homogenate with
an anti-p52 subunit specific antibody, we cannot exclude that NF-
kB phosphorylation and translocation into the nucleus and/or
expression/activation of other subunits, such as p65, equally
important for NF-kB transcriptional activity, could occur in
response to MCT. Whether there is a contribution of inflamma-
tion to PH pathogenesis at an earlier time point, possibly in the
first few days or weeks after MCT administration, as suggested by
others [21], has not been addressed in the present study.
COX-2 KD mice revealed <50% reduction in PGI2 lung
production after MCT in comparison to WT mice. We did not
detect significant differences in COX-2 and COX-1 levels between
saline- and MCT-treated mice by Western blot, qPCR or
immunostaining of lung sections and, as expected, COX-2 mRNA
and protein expression were severely abrogated (<90%) in COX-
2 KD mice. Since PGIS, the enzyme responsible for specific
conversion of COX-derived PGH2 into PGI2, and COX-1 protein
expression were not affected by MCT treatment, taken together
these results are consistent with lung COX-2 being a major source
Figure 8. Oxidative stress is exacerbated in lungs after MCT treatment. A. Detection of nitrated tyrosine residues in whole lung
homogenates in WT and COX-2 KD mice after MCT administration compared to saline-treated mice. The antibody detected a specific band (Nitrotyr)
at >65 kDa. b-actin is shown as loading control. Each lane represents lung proteins from one mouse. B. Quantitation of band intensities expressed as
ratio with b-actin, in arbitrary units (AU). WT/saline, n=3; WT/MCT, n=6; COX-2 KD/saline, n=3; COX-2 KD/MCT, n=4. * p,0.05 vs saline.
doi:10.1371/journal.pone.0023439.g008
Figure 9. NOX-4 is induced in response to MCT. NOX-4 mRNA
expression detected by quantitative RT-PCR in whole lung extracts.
Results were expressed as fold-change relative to WT/saline after
normalization to endogenous control GADPH. WT/saline, n=5; WT/
MCT, n=9; COX-2 KD/saline, n=4; COX-2 KD/MCT, n=6) *, p,0.05 vs
saline.
doi:10.1371/journal.pone.0023439.g009
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(ONOO
2), generated by the reaction of O2
.2 with nitric oxide at
diffusion-limited rates in settings of oxidative stress, can oxidize
critical sulphydryl and thioether groups and lead to tyrosine
nitration in numerous proteins, including PGIS, reducing their
catalytic activity. In MCT-treated mice nitrated tyrosine content
was increased compared to saline-treated mice and since in COX-
2 KD mice oxidative stress was exacerbated compared to WT,
PGIS nitration is likely to occur. Impaired PGIS activity in these
mice, together with severe down regulation of COX-2, could both
be responsible for the marked PGI2 reduction, despite no overall
PGIS protein expression change in MCT-treated COX-2 KD
lungs. Lastly, reduction of PGI2 generation in settings of oxidative
stress and reduced COX-2 activity, as in COX-2 KD mice after
MCT administration, could divert unmetabolized arachidonic
acid and/or PGH2 to other lipid metabolites (HETEs, isopros-
tanes) that may also contribute to impaired endothelial-dependent
vasorelaxation and vasoconstriction in pulmonary vasculature
causing increased pulmonary vascular resistance. To this end, Zou
et al. [61,62] demonstrated that hypoxia-reoxygenation or
angiotensin II caused PGIS nitration in bovine coronary arteries
and not only reduced PGI2 generation but also triggered PGH2-
induced vasospasms and thrombosis via TXA2 receptor activation.
Whether PGIS nitration and diversion of arachidonic acid and/or
PGH2 to vasoconstrictor lipid metabolites, that could impair
pulmonary arterial relaxation, occur in response to MCT in
COX-2 KD mice compared to WT will be the focus of future
studies.
One major limitation of this study is that MCT, despite
sustained pulmonary oxidative effects exacerbated by the lack of
COX-2, unexpectedly induced only modest hemodynamic
changes in mice. In our preliminary studies, MCT in the range
50–300 mg/kg BW for 4 wk was not effective in increasing right
ventricular pressure and pulmonary arterial muscularization,
despite a modest increase, without reaching statistical significance,
in the 300 mg/kg BW-treated group. These pilot studies motivated
us to increase the regimen of weekly MCT administration to
600 mg/kg BW for 10 wk in order to observe sustained
pulmonary effects in mice. This dose is approximately 10-fold
higher than the one commonly used in rats (60–75 mg/kg BW).
Species-specific differences in hepatic enzymes essential for MCT
transformation into the pyrrole active metabolite account for a
well-known resistant phenotype of mice to MCT pulmonary
effects compared to rats [26,27]. Notably, MCT administered
weekly at 600 mg/kg was in large part tolerated by WT mice (3 of
14 died) but caused duress in COX-2 KD mice (14 of 19 died or
required euthanasia). Acute hepatic necrosis was evident in some
of the MCT-treated mice that died or required euthanasia and it
was more pronounced in COX-2 KD mice. Hepatic toxicity
associated with MCT administration in experimental animals has
been correlated with a reduction in glutathione and anti-oxidant
levels in the liver [63]. The exact mechanisms by which low COX-
2 levels increased MCT-induced hepatic toxicity are unknown but
they may be related to microsomal PGE synthase (mPGES-1), an
inducible glutathione-dependent enzyme of the MAPEG family,
whose expression and activity are closely linked to COX-2 [64,65].
Further studies will be necessary to investigate MCT-induced
hepatic toxicity in COX-2 KD mice.
MCT at 600 mg/kg BW has recently been employed by several
other investigators to induce PH in mice [28,29,30,31,35];
however, in our study, this MCT regimen caused only a mild
increase in pulmonary arterial pressure in mice, a modest increase
in vasoconstrictors and mild chronic inflammation, without
evident pulmonary vascular or cardiac remodeling. Whether
longer treatments with MCT at this dose will be required to induce
severe pulmonary and cardiac morphological and hemodynamic
changes in mice is not clear. However, the fact that 3 of 14 MCT-
treated WT mice died during this study and revealed hepatic
necrosis suggests that hepatic toxicity may limit the use of MCT at
600 mg/kg for more than 10 wk.
In conclusion, the present study supports the hypothesis that
oxidative stress-induced endothelial dysfunction, vasoconstriction
and increased tendency for platelet activation in pulmonary
vasculature and mild inflammation, exacerbated by the lack of
COX-2, are the major determinants of PH at early stages of the
disease when vascular and cardiac remodeling are not still
apparent. We propose that NOX-4 inhibition or other therapeutic
interventions that limit oxidative stress may prevent the progres-
sion of PH while COX-2 inhibitors may be hazardous in early
stages of the disease. Furthermore, our study underscores the
difficulty of using MCT in mice as a model of PH, due to the
narrow therapeutic window between pulmonary effects and
hepatic toxicity and points out that novel animal models are
needed to study the pathogenesis of this complex disease.
Materials and Methods
Study design
All animal procedures were approved by Queen’s University
Animal Care Committee (protocol Funk-2009-027). WT and
COX-2 knock down (COX-2 KD) inbred mice (C57BL/6 genetic
background selected by The Jackson Laboratory speed congenics
panel and further back-crossed to .99% C57BL/6) were housed
in the same room on a 12h light/dark cycle and had access to
standard chow and water ad libitum. COX-2 KD mice are
characterized by severely suppressed (80-90%) COX-2 expression,
as previously described in detail [20]. Monocrotaline (MCT,
Sigma-Aldrich) solution was freshly prepared by dissolution in
warm saline and prepared to pH <7.0. WT and COX-2 KD mice
(males/females, 8–10 weeks old) received either 10 ml MCT
solution/g body weight (BW; 600 mg/kg), intra-peritoneally, once
weekly for 10 weeks or saline. Body weights were recorded before
each MCT or saline administration. Clinical condition, including
any sign of distress was carefully monitored and recorded during
the study.
Echocardiography to assess right ventricular
hypertrophy, pulmonary artery and left ventricular
function
After the final MCT administration, all surviving mice
underwent echocardiography analysis (VisualSonics Vevo770,
Toronto, Canada). During the procedure, isofluorane/O2 admin-
istration was administered by facemask to keep mice lightly
anesthetized with heart rates in the range of 400–500 bpm. The
right ventricle was visualized in a right parasternal long axis view
with a 704 RMV scan-head. Right ventricular wall thickness was
measured from images acquired in M-mode, using the depth
interval (mm) generic measurement tool (Vevo770 v3.0 software,
VisualSonics). Doppler flow images were recorded from the left
parasternal long axis view with the 707 B scanhead slightly
pointing to the left shoulder to visualize the pulmonary artery.
Volume measurement was acquired at the level of the pulmonary
valve and several indices of pulmonary artery blood flow (velocity-
time integral, mean and peak pressure gradient and mean and
peak velocity) were assessed using the pulmonary valve protocol
measurement tool. Left ventricular function and dimensions
(cardiac output, stroke volume, ejection fraction, fractional
shortening, left ventricular diameter in systole and diastole, left
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LV wall trace measurement tool from M-mode images acquired
from a left parasternal short axis view at the level of the papillary
muscles.
Measurement of right ventricular pressure
Right ventricular pressures were measured as an index of
pulmonary artery pressure. Briefly, mice were anesthetized with
sodium pentobarbital (32 mg/g BW), placed on a heating pad and
mechanically ventilated through a 22-gauge cannula (120 breaths/
min, Harvard Apparatus rodent ventilator). By pulling the
hyphoid cartilage upwards, the thoracic cage was gently opened
from the diaphragm and through the sternum to expose the heart.
Tissue was cauterized when necessary to minimize any blood loss.
The exposed heart was superfused with warm saline during the
procedure. The tip of a 25G needle, previously immersed in
heparin solution (Hepalean, 10,000 USP units/ml, Organon,
Toronto, Canada), was inserted into the right ventricle by gently
piercing the wall, using the right coronary artery as guide. The tip
of a radio-telemetry pressure transducer (TA11PA-C10, Data
Systems International, DSI) was inserted through the small
aperture after needle retraction. Pressure waveforms were
monitored in real-time using the ‘‘trace and save’’ setting in the
continuous sampling acquisition mode (Dataquest ART system,
DSI) and recorded for at least 10 min for each mouse. Right
ventricular pressures were calculated by averaging 15 s intervals of
continuous recording.
Tissue harvesting
At the end of right ventricular pressure measurements,
bronchoalveolar lavage (BAL) fluid was collected by two intra-
tracheal washes, with 800 ml ice-cold PBS. BAL fluid was
centrifuged at 1200 rpm for 8 min at 4uC to remove any cellular
component and the supernatant stored at 280uC for prostanoid
and cytokine analysis. The BAL pellet was resuspended in 0.5 ml
PBS and 50 ml of cell suspension was cytospun (800 rpm, 4 min)
onto Superfrost glass slides (Fisher Scientific) and used for
differential cell count after Wright’s staining. Heparinized blood
was collected via cardiac puncture and plasma was separated by
centrifugation at 2500 rpm for 10 min at 4uC. Heart and lungs
were removed en-bloc and washed with PBS on ice. The right lung
was removed and immediately immersed in RNAlater (Ambion),
held at 4uC overnight and then stored at 280uC pending further
analysis. The remaining left lung and heart were gravity-fixed
overnight with 10% buffered formalin via an intra-tracheal 22G
cannula. Hearts were sectioned transversely and immersed in 10%
buffered formalin until preparation of sections and immunostain-
ing to assess cardiac hypertrophy. Lungs were paraffin-embedded
and processed as described below.
Lung histopathology analyses
For routine microscopic evaluation lung lobes were embedded
in paraffin blocks, sectioned and stained with hematoxylin-eosin
(H&E). To assess pulmonary vascular remodeling and COX-2
expression after MCT treatments, 8 mm lung sections were
prepared from paraffin-embedded lungs. To assure a standardized
and unbiased comparison between animals, taking into account
the complex branching structure of the lungs, longitudinal sections
were prepared by systematic sampling at the 10
th,1 5
th,2 0
th and
25
th consecutive 8 mm interval for each animal (80, 120, 160 and
240 mm depth), using the pulmonary artery as hallmark. Lung
sections were rehydrated in PBS and immunolabeled with a
specific marker for smooth muscle (Actin, a-smooth muscle,
Immunohistology kit, Sigma-Aldrich) or with a rabbit polyclonal
anti-COX-2 antibody (Cayman Chemical #160126). COX-2
protein was detected with a Vectastain ABC kit (rabbit IgG) and
DAB substrate following the manufacturer’s instructions (Vector-
Labs). All sections were counterstained with H&E.
Dihydroethidine fluorescence
Dihydroethidine (DHE) was used to assess superoxide anion
(O2
. 2) levels in lung tissues as an index of oxidative stress, as
described by others [57,66,67,68,69]. In the presence of O2
. 2,
DHE is oxidized to ethidium, which intercalates with cellular
DNA and gives a red fluorescent signal. Right lungs were frozen
and kept at 280uC until OCT embedding and sectioning at
220uC (20 mm). DHE solution (10 mM) was freshly prepared in
DMSO and diluted in PBS to 10 mM working solution. Lung
sections were kept frozen until washed on ice with cold PBS and
incubated with DHE solution at 37uC for 1 h. Sections were then
washed in PBS and mounted with Permount. Digital images were
captured with a Leica DM IRB microscope, a Q imaging digital
camera and OpenLab 4.0.2 software. To assure consistency of
staining, all lung sections were processed in the same day and
imaging acquisition parameters (exposure time, gain and offset)
were kept constant for all sections. For DHE quantitative analysis,
fluorescence intensities were measured automatically by setting the
threshold value to 180 on a color scale 0–256 (ImageProPlus 5.1)
and expressed as integrated optical density (IOD). At least 3
images (696 x 520 pixels; 10x objective) from 2 different lung
sections were acquired for each treatment group. Digital images
were first quantified in a treatment-blinded fashion and then
fluorescence values pertaining to the same treatment group were
averaged. Intensity values below 180 represent background
fluorescence from a saline-treated lung section used as reference.
Western blot analysis
Whole lung homogenates were prepared by mechanical
disruption on ice in a glass tissue grinder, with T-Per lysis buffer
(Pierce) and freshly added protease inhibitor cocktail (Roche).
Proteins were separated by 10% SDS-PAGE and transferred to
PVDF membranes. After overnight blocking in 5% milk-TBS
solution, membranes were incubated with the following primary
antibodies: anti-COX-2 (Cayman Chemical, cat #160126), anti-
COX-1 (Cayman Chemical, cat # 160109), anti-PGIS (Cayman
Chemical, cat # 100023), anti-eNOS (AnaSpec, cat # 53458),
anti-NF-kB (Santa Cruz, cat # sc-298), anti-nitrotyrosine
(Cayman Chemical, cat # 10189540) and anti-b-actin (Sigma-
Aldrich, cat # A5441). Protein bands were visualized by
incubation with appropriate HRP-conjugated secondary antibod-
ies and chemiluminescent reagent (GE-Amersham). Blot images
were acquired with a FluorChem 8900 instrument (Alpha
Innotech) and quantitated with ImageJ (www.nih.gov).
Real-time PCR
Lungs, immersed in RNAlater (Ambion) immediately upon
harvest to stabilize RNA, were homogenized in TRIzol (Invitro-
gen). Total RNA was extracted with chloroform and precipitated
in isopropanol, as per the manufacturer’s instructions. Total RNA
(1 mg) was reverse-transcribed using iScript cDNA synthesis kit
(BioRad). cDNA (150 ng) was added to 10 ml iTaq SYBR Green
Supermix with ROX (BioRad) in the presence of 2 ml each of
sense/antisense primers (200 mM final concentration). Optimal
primer pairs were designed to span an intron-exon junction and to
produce a short amplicon (<150 bp) in order to maximize the
specificity and efficiency of amplification reactions (PrimerExpress
v.2 software). Primer sequences were as follows: endothelin-1
receptor-A forward 59-CTTCCTGCAGAAGTCCTCCG-39 and
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ward 59-AGCCAGGCAGCAAATCCTT-39 and reverse 59-AT-
TCCCCACGGTTTTGACA-39; tumor necrosis factor-a (TNFa
forward 59- ATTCCTGCTTGTGGCAGGG-39 and reverse 59-
GGTGGTTTGCTACGACGTGG-39 and GAPDH forward 59-
CTGGAGAAACCTGCCAAGTA-39 and reverse 59-TGTTGC-
TGTAGCCGTATTCA-39. The following primer sequences were
kindly provided by Dr Lars Bellner (Department of Pharmacology,
New York Medical College, Valhalla, NY, USA): HO-1 forward
59-AAGCCGAGAATGCTGAGTTCA-39 and reverse 59- GCC-
GTGTAGATATGGTACAAGGA-39; NADPH oxidase (NOX-
2/gp91phox subunit: forward 59-TGAATGCCAGAGTCGGG-
ATTT-39 and reverse 59-CCCCCTTCAGGGTTCTTGATTT-
39 and NOX-4 subunit: forward 59-GAAGGGGTTAAACAC-
CTCTGC-39 and reverse 59-ATGCTCTGCTTAAACACAA-
TCCT-39); extracellular superoxide dismutase (EC-SOD) forward
59-CCTTCTTGTTCTACGGCTTGC-39 and reverse 59-TCG-
CCTATCTTCTCAACCAGG-39. Real time PCR reactions were
carried out with an Applied Biosystems 7500 Real Time PCR
instrument using the following thermocycler conditions: 95uC/
1 min, 95uC/5 s and 60uC/45 s (40 cycles). Dissociation curve
analysis (melting curve) following each amplification reaction and
1% agarose gel analysis confirmed the generation of primer-
specific products. Relative quantification of RNA expression was
determined using the Ct analysis settings of 7500 System Sequence
Detection Software v.1.3 based on the DDCt comparative method.
In order to consistently compare samples analyzed in different
days and assay plates, we used 1 mg cDNA prepared from a mouse
total RNA reference sample, consisting of a pool of 11 mouse cell
lines (Stratagene QPCR Mouse Reference Total RNA, cat. #
750600). Results were expressed as fold-change relative to this
reference cDNA using GAPDH as endogenous control gene.
Prostanoid and cytokine analysis
TXB2 and 6-keto-PGF1a non-enzymatic metabolites of TXA2
and PGI2 respectively, and PGE2 were assessed in BAL by enzyme
immunoassay (Cayman Chemical). Interleukin-6 (IL-6), interleu-
kin-10 (IL-10), monocyte chemoattractant protein-1 (MCP-1),
interferon-c (IFN-c), interleukin-12p70 (IL-12p70) and TNFa
were analyzed in BAL and plasma samples using BD cytometric
bead array, as per the manufacturer’s recommendations (Mouse
inflammation kit cat # 552364, BD).
Cell count in bronchoalveolar lavage fluid
Wright’s-stained cytospin preparations of air-dried bronchoal-
veolar lavage fluid were assessed microscopically, and the relative
numbers of each cell type were determined and expressed as a
percentage of the total cell population present.
Statistical analysis
Data are expressed as mean6SE; Student’s t-test was used for
comparisons between different treatment groups; p values ,0.05
were considered significant.
Supporting Information
Figure S1 Kaplan-Meier survival curves for MCT-
treated WT (n=14) and COX-2 KD (n=19) mice. Dashed
line indicates no loss in survival of saline-treated WT (n=6) and
COX-2 KD (n=6) mice. *, p=0.0006.
(TIF)
Table S1 Left Ventricular function is not altered by
MCT treatment. Indices of left ventricular function were
measured in WT and COX-2 KD mice, treated with saline or
MCT, from M-mode images of the left ventricle acquired by
echocardiography, as described in Methods. CO, cardiac output;
SV, stroke volume; EF, ejection fraction; FS, fractional shortening,
LVDs, left ventricular diameter in systole; LVDd, left ventricular
diameter in diastole; LVVs, left ventricular volume in systole;
LVVd, left ventricular volume in diastole. Number of mice for
each group is in parentheses. Mean6SE.
(DOCX)
Acknowledgments
We thank Tim St. Amand for the preparation of tissue sections, John
Lawson for urinary PGE metabolite measurements and Dr. Harrison W.
Farber for helpful suggestions and comments.
Author Contributions
Conceived and designed the experiments: FS CDF. Performed the
experiments: FS MR PVT. Analyzed the data: FS MR PVT CDF.
Contributed reagents/materials/analysis tools: FS CDF. Wrote the paper:
FS PVT CDF.
References
1. Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from
arteries transforms prostaglandin endoperoxides to an unstable substance that
inhibits platelet aggregation. Nature 263: 663–665.
2. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, et al. (2002) Role of
prostacyclin in the cardiovascular response to thromboxane A2. Science 296:
539–541.
3. Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, et al. (2005) COX-2-derived
prostacyclin modulates vascular remodeling. Circ Res 96: 1240–1247.
4. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, et al.
(1992) An imbalance between the excretion of thromboxane and prostacyclin
metabolites in pulmonary hypertension. N Engl J Med 327: 70–75.
5. Fuse S, Kamiya T (1994) Plasma thromboxane B2 concentration in pulmonary
hypertension associated with congenital heart disease. Circulation 90: 2952–2955.
6. Gaine S (2000) Pulmonary hypertension. Jama 284: 3160–3168.
7. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, et al. (1999)
Prostacyclin synthase expression is decreased in lungs from patients with severe
pulmonary hypertension. Am J Respir Crit Care Med 159: 1925–1932.
8. Lee JD, Taraseviciene-Stewart L, Keith R, Geraci MW, Voelkel NF (2005) The
expression of prostacyclin synthase is decreased in the small pulmonary arteries
from patients with emphysema. Chest 128: 575S.
9. Geraci M, Gao B, Shepherd D, Allard J, Curiel D, et al. (1998) Pulmonary
prostacyclin synthase overexpression by adenovirus transfection and in
transgenic mice. Chest 114: 99S.
10. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, et al. (1999)
Pulmonary prostacyclin synthase overexpression in transgenic mice protects
against development of hypoxic pulmonary hypertension. J Clin Invest 103:
1509–1515.
11. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, et al. (2001)
Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.
Am J Respir Crit Care Med 164: 314–318.
12. Friedman R, Mears JG, Barst RJ (1997) Continuous infusion of prostacyclin
normalizes plasma markers of endothelial cell injury and platelet aggregation in
primary pulmonary hypertension. Circulation 96: 2782–2784.
13. Farber HW, Loscalzo J (1999) Prothrombotic mechanisms in primary
pulmonary hypertension. J Lab Clin Med 134: 561–566.
14. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, et al. (1999)
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human
pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96:
272–277.
15. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, et al. (2008) Cardiovascular
risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety
analysis. Circulation 117: 2104–2113.
16. Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O, et al. (2004)
Intravascular thrombosis after hypoxia-induced pulmonary hypertension:
regulation by cyclooxygenase-2. Circulation 110: 2701–2707.
17. Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, et al. (2008)
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hyperten-
sion and intravascular thrombosis. J Pharmacol Exp Ther 326: 51–58.
18. Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, et al. (2008) Absence
of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and
COX-2 Knockdown Mice in PH
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23439enhances contractility of vascular smooth muscle cells. Circulation 117:
2114–2122.
19. Fredenburgh LE, Ma J, Perrella MA (2009) Cyclooxygenase-2 inhibition and
hypoxia-induced pulmonary hypertension: effects on pulmonary vascular
remodeling and contractility. Trends Cardiovasc Med 19: 31–37.
20. Seta F, Chung AD, Turner PV, Mewburn JD, Yu Y, et al. (2009) Renal and
cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul
Integr Comp Physiol 296: R1751–1760.
21. Dumitrascu R, Koebrich S, Dony E, Weissmann N, Savai R, et al. (2008)
Characterization of a murine model of monocrotaline pyrrole-induced acute
lung injury. BMC Pulm Med 8: 25.
22. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, et al. (2006)
Activation of soluble guanylate cyclase reverses experimental pulmonary
hypertension and vascular remodeling. Circulation 113: 286–295.
23. Raoul W, Wagner-Ballon O, Saber G, Hulin A, Marcos E, et al. (2007) Effects of
bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary
hypertension in mice. Respir Res 8: 8.
24. Song Y, Coleman L, Shi J, Beppu H, Sato K, et al. (2008) Inflammation,
endothelial injury, and persistent pulmonary hypertension in heterozygous
BMPR2-mutant mice. Am J Physiol Heart Circ Physiol 295: H677–690.
25. Aliotta JM, Keaney PJ, Warburton RR, DelTatto M, Dooner MS, et al. (2009)
Marrow cell infusion attenuates vascular remodeling in a murine model of
monocrotaline-induced pulmonary hypertension. Stem Cells Dev 18: 773–782.
26. Reid MJ, Lame MW, Morin D, Wilson DW, Segall HJ (1998) Involvement of
cytochrome P450 3A in the metabolism and covalent binding of 14C-
monocrotaline in rat liver microsomes. J Biochem Mol Toxicol 12: 157–166.
27. Deyo JA, Reed RL, Buhler DR, Kerkvliet NI (1994) Role of metabolism in
monocrotaline-induced immunotoxicity in C57BL/6 mice. Toxicology 94:
209–222.
28. George J, D’Armiento J (2010) Transgenic expression of human matrix
metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hy-
pertension in mice. J Hypertens.
29. Nishii Y, Gabazza EC, Fujimoto H, Nakahara H, Takagi T, et al. (2006)
Protective role of protein C inhibitor in monocrotaline-induced pulmonary
hypertension. J Thromb Haemost 4: 2331–2339.
30. Qin L, D’Alessandro-Gabazza CN, Aoki S, Gil-Bernabe P, Yano Y, et al. (2010)
Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable
fibrinolysis inhibitor. J Thromb Haemost 8: 808–816.
31. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, et al. (2009)
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2
gene transfer. Hypertension 54: 365–371.
32. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal
models of pulmonary arterial hypertension: the hope for etiological discovery
and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:
L1013–1032.
33. Butler WH (1970) An ultrastructural study of the pulmonary lesion induced by
pyrrole derivatives of the pyrrolizidine alkaloids. J Pathol 102: 15–19.
34. Czer GT, Marsh J, Konopka R, Moser KM (1986) Low-dose PGI2 prevents
monocrotaline-induced thromboxane production and lung injury. J Appl Physiol
60: 464–471.
35. Goto J, Ishikawa K, Kawamura K, Watanabe Y, Matumoto H, et al. (2002)
Heme oxygenase-1 reduces murine monocrotaline-induced pulmonary inflam-
matory responses and resultant right ventricular overload. Antioxid Redox
Signal 4: 563–568.
36. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T (1988) A novel
peptide vasoconstrictor, endothelin, is produced by vascular endothelium and
modulates smooth muscle Ca2+ channels. J Hypertens;Suppl 6): S188–191.
37. Hassoun PM, Thappa V, Landman MJ, Fanburg BL (1992) Endothelin 1:
mitogenic activity on pulmonary artery smooth muscle cells and release from
hypoxic endothelial cells. Proc Soc Exp Biol Med 199: 165–170.
38. Ohlstein EH, Arleth A, Bryan H, Elliott JD, Sung CP (1992) The selective
endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated
mitogenesis. Eur J Pharmacol 225: 347–350.
39. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma
endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann
Intern Med 114: 464–469.
40. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial
hypertension. N Engl J Med 351: 1425–1436.
41. Galie N, Manes A, Branzi A (2004) The endothelin system in pulmonary arterial
hypertension. Cardiovasc Res 61: 227–237.
42. Gryglewski RJ, Korbut R, Ocetkiewicz A (1978) Generation of prostacyclin by
lungs in vivo and its release into the arterial circulation. Nature 273: 765–767.
43. Shah M, Patel K, Sehgal PB (2005) Monocrotaline pyrrole-induced endothelial
cell megalocytosis involves a Golgi blockade mechanism. Am J Physiol Cell
Physiol 288: C850–862.
44. Mukhopadhyay S, Shah M, Patel K, Sehgal PB (2006) Monocrotaline pyrrole-
induced megalocytosis of lung and breast epithelial cells: Disruption of plasma
membrane and Golgi dynamics and an enhanced unfolded protein response.
Toxicol Appl Pharmacol 211: 209–220.
45. Frey RS, Ushio-Fukai M, Malik AB (2009) NADPH oxidase-dependent
signaling in endothelial cells: role in physiology and pathophysiology. Antioxid
Redox Signal 11: 791–810.
46. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR (2005)
The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth
muscle. Cardiovasc Res 65: 495–504.
47. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, et al. (2004) Nox4 as the
major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109:
227–233.
48. Morham SG LR, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC,
Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O (1995) Prostaglandin
synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:
473–482.
49. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, et al. (1995) Renal
abnormalities and an altered inflammatory response in mice lacking cycloox-
ygenase II. Nature 378: 406–409.
50. Archer S, Rich S (2000) Primary pulmonary hypertension: a vascular biology
and translational research ‘‘Work in progress’’. Circulation 102: 2781–2791.
51. Meyrick B, Gamble W, Reid L (1980) Development of Crotalaria pulmonary
hypertension: hemodynamic and structural study. Am J Physiol 239: H692–702.
52. Rosenberg HC, Rabinovitch M (1988) Endothelial injury and vascular reactivity
in monocrotaline pulmonary hypertension. Am J Physiol 255: H1484–1491.
53. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res 87: 840–844.
54. Celermajer DS, Cullen S, Deanfield JE (1993) Impairment of endothelium-
dependent pulmonary artery relaxation in children with congenital heart disease
and abnormal pulmonary hemodynamics. Circulation 87: 440–446.
55. Celermajer DS, Dollery C, Burch M, Deanfield JE (1994) Role of endothelium
in the maintenance of low pulmonary vascular tone in normal children.
Circulation 89: 2041–2044.
56. Toporsian M, Jerkic M, Zhou YQ, Kabir MG, Yu LX, et al. Spontaneous
adult-onset pulmonary arterial hypertension attributable to increased endothelial
oxidative stress in a murine model of hereditary hemorrhagic telangiectasia.
Arterioscler Thromb Vasc Biol 30: 509–517.
57. Grobe AC, Wells SM, Benavidez E, Oishi P, Azakie A, et al. (2006) Increased
oxidative stress in lambs with increased pulmonary blood flow and pulmonary
hypertension: role of NADPH oxidase and endothelial NO synthase.
Am J Physiol Lung Cell Mol Physiol 290: L1069–1077.
58. Konduri GG, Bakhutashvili I, Eis A, Pritchard K, Jr. (2007) Oxidant stress from
uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with
persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 292:
H1812–1820.
59. Wunderlich C, Schmeisser A, Heerwagen C, Ebner B, Schober K, et al. (2008)
Chronic NOS inhibition prevents adverse lung remodeling and pulmonary
arterial hypertension in caveolin-1 knockout mice. Pulm Pharmacol Ther 21:
507–515.
60. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, et al. (2009) Resveratrol
prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension
54: 668–675.
61. Zou MH, Bachschmid M (1999) Hypoxia-reoxygenation triggers coronary
vasospasm in isolated bovine coronary arteries via tyrosine nitration of
prostacyclin synthase. J Exp Med 190: 135–139.
62. Zou M, Jendral M, Ullrich V (1999) Prostaglandin endoperoxide-dependent
vasospasm in bovine coronary arteries after nitration of prostacyclin synthase.
Br J Pharmacol 126: 1283–1292.
63. Miranda CL, Carpenter HM, Cheeke PR, Buhler DR (1981) Effect of
ethoxyquin on the toxicity of the pyrrolizidine alkaloid monocrotaline and on
hepatic drug metabolism in mice. Chem Biol Interact 37: 95–107.
64. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999) Identification of
human prostaglandin E synthase: a microsomal, glutathione-dependent,
inducible enzyme, constituting a potential novel drug target. Proc Natl Acad
Sci U S A 96: 7220–7225.
65. Matsumoto H, Naraba H, Murakami M, Kudo I, Yamaki K, et al. (1997)
Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads
to preferred production of prostaglandin E2 over thromboxane and prostaglan-
din D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem
Biophys Res Commun 230: 110–114.
66. Kim-Mitsuyama S, Yamamoto E, Tanaka T, Zhan Y, Izumi Y, et al. (2005)
Critical role of angiotensin II in excess salt-induced brain oxidative stress of
stroke-prone spontaneously hypertensive rats. Stroke 36: 1083–1088.
67. Zanetti M, d’Uscio LV, Peterson TE, Katusic ZS, O’Brien T (2005) Analysis of
superoxide anion production in tissue. Methods Mol Med 108: 65–72.
68. Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, et al. (2006) Reversal
of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial
nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am
Coll Cardiol 47: 2536–2544.
69. Lodi F, Cogolludo A, Duarte J, Moreno L, Coviello A, et al. (2006) Increased
NADPH oxidase activity mediates spontaneous aortic tone in genetically
hypertensive rats. Eur J Pharmacol 544: 97–103.
COX-2 Knockdown Mice in PH
PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e23439